公开(公告)号：US20180333489A1

公开(公告)日：2018-11-22

申请号：US15950974

申请日：2018-04-11

申请人： Kiniksa Pharmaceuticals, Ltd.

发明人： Mark Cornell Manning ,  Zahra Shahrokh ,  Dave Nichols ,  Phillip M. Levesque ,  Ryan Erik Holcomb

IPC分类号： A61K39/395 ,  C07K16/24

CPC分类号： A61K39/3955 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/00 ,  C07K16/24 ,  C07K16/2866 ,  C07K2317/14 ,  C07K2317/94

摘要： The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.

公开(公告)号：US20190054169A1

公开(公告)日：2019-02-21

申请号：US16179219

申请日：2018-11-02

申请人： Kiniksa Pharmaceuticals, Ltd.

发明人： Mark Cornell Manning ,  Zahra Shahrokh ,  Dave Nichols ,  Phillip M Levesque ,  Ryan Erik Holcomb

IPC分类号： A61K39/395 ,  C07K16/24 ,  A61K39/00

CPC分类号： A61K39/3955 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/00 ,  C07K16/24 ,  C07K16/2866 ,  C07K2317/14 ,  C07K2317/94

摘要： The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.

公开(公告)号：US11141479B2

公开(公告)日：2021-10-12

申请号：US16551326

申请日：2019-08-26

申请人： Kiniksa Pharmaceuticals, Ltd.

发明人： Mark Cornell Manning ,  Zahra Shahrokh ,  Dave Nichols ,  Philip M Levesque ,  Ryan Erik Holcomb

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  C07K16/24 ,  A61K39/00

摘要： The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.

公开(公告)号：US20200061188A1

公开(公告)日：2020-02-27

申请号：US16551326

申请日：2019-08-26

申请人： Kiniksa Pharmaceuticals, Ltd.

发明人： Mark Cornell Manning ,  Zahra Shahrokh ,  Dave Nichols ,  Philip M Levesque ,  Ryan Erik Holcomb

IPC分类号： A61K39/395 ,  C07K16/24 ,  C07K16/28 ,  C07K16/00

摘要： The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.

公开(公告)号：US10391170B2

公开(公告)日：2019-08-27

申请号：US16179219

申请日：2018-11-02

申请人： Kiniksa Pharmaceuticals, Ltd.

发明人： Mark Cornell Manning ,  Zahra Shahrokh ,  Dave Nichols ,  Phillip M Levesque ,  Ryan Erik Holcomb

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  C07K16/24 ,  A61K39/00

摘要： The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.

公开(公告)号：US20220062414A1

公开(公告)日：2022-03-03

申请号：US17469797

申请日：2021-09-08

申请人： Kiniksa Pharmaceuticals, Ltd.

发明人： Mark Cornell Manning ,  Zahra Shahrokh ,  Dave Nichols ,  Philip M Levesque ,  Ryan Erik Holcomb

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  C07K16/24

摘要： The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.